Regado Biosciences (Regado Biosciences) Gross Margin % : 0.00% (As of Jun. 2016)

View and export this data going back to . Start your Free Trial

What is Regado Biosciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Regado Biosciences's Gross Profit for the three months ended in Jun. 2016 was $1.06 Mil. Regado Biosciences's Revenue for the three months ended in Jun. 2016 was $1.06 Mil. Therefore, Regado Biosciences's Gross Margin % for the quarter that ended in Jun. 2016 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for Regado Biosciences's Gross Margin % or its related term are showing as below:

RGDO' s Gross Margin % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 100
Current: 100

During the past 5 years, the highest Gross Margin % of Regado Biosciences was 100.00%. The lowest was 0.00%. And the median was 0.00%.

RGDO's Gross Margin % is not ranked
in the Biotechnology industry.
Industry Median: 59.33 vs RGDO: 100.00

Regado Biosciences had a gross margin of N/A% for the quarter that ended in Jun. 2016 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Regado Biosciences was 0.00% per year.

Regado Biosciences Gross Margin % Historical Data

The historical data trend for Regado Biosciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regado Biosciences Gross Margin % Chart

Regado Biosciences Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Gross Margin %

Regado Biosciences Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Gross Margin %	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Regado Biosciences's Gross Margin %

For the Biotechnology subindustry, Regado Biosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regado Biosciences's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regado Biosciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Regado Biosciences's Gross Margin % falls into.

Regado Biosciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Regado Biosciences's Gross Margin for the fiscal year that ended in Dec. 2015 is calculated as

Gross Margin % (A: Dec. 2015 )	=	Gross Profit (A: Dec. 2015 )	/	Revenue (A: Dec. 2015 )
	=	0	/	0
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0 - 0)	/	0
	=	N/A %

Regado Biosciences's Gross Margin for the quarter that ended in Jun. 2016 is calculated as

Gross Margin % (Q: Jun. 2016 )	=	Gross Profit (Q: Jun. 2016 )	/	Revenue (Q: Jun. 2016 )
	=	1.1	/	1.058
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(1.058 - 0)	/	1.058
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Regado Biosciences (NAS:RGDO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Regado Biosciences had a gross margin of N/A% for the quarter that ended in Jun. 2016 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Regado Biosciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of Regado Biosciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Regado Biosciences (Regado Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regado Biosciences Inc (NAS:RGDO) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.tobiratherapeutics.com

Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.

Executives

Domain Parters Vii L P	10 percent owner	ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Associates Domain	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p.	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Brian K Halak	10 percent owner	C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Kim P. Kamdar	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber	director	C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Patrick J Heron	director	550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Dp Vii Associates Lp	10 percent owner	ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Jeffrey H Cooper	director	BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Frazier Healthcare V, Lp	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Christopher Peetz	officer: Chief Financial Officer	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Andrew J. Fromkin	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Carol L Brosgart	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Regado Biosciences (Regado Biosciences) Headlines

No Headlines